Literature DB >> 33911760

A Case of Generalized Lichen Sclerosus et Atrophicus.

Eun Hye Hong1, Min Kyun An1, Eun Byul Cho1, Eun Joo Park1, Kwang Joong Kim1, Kwang Ho Kim1.   

Abstract

A 62-year-old female, with previous history of asthma and hypertension, presented with generalized hyperpigmented skin lesion, found a year ago. Physical examination revealed brown colored lichenified and sclerotic patches on the lower abdomen and flexural areas of extremities. Punch biopsy was performed and histopathological examination revealed hyperkeratosis, follicular plugging and thinning in epidermis. In dermoepidermal junction, cleft like space separating atrophic epidermis and dermis was seen. Also, lichenoid lymphocytic infiltration was observed in mid-dermis. Based on clinical and histopathological findings, a diagnosis of generlaized lichen sclerosus et atrophicus (LSA) was made. Other laboratory examinations were unremarkable. As there is no standard treatment for LSA, the patient received various treatments including topical steroid, tacrolimus and narrow-band ultraviolet B therapy. The skin lesion has softened and its color improved after treatment. LSA is defined as infrequent chronic inflammatory dermatosis with anogenital and extragenital manifestations. Generalized type is rare and genital involvement is the most frequent and often the only site of involvement. We report this case as it is an uncommon type of LSA with generalized hyperpigmented and sclerotic skin lesion in a postmenopausal female patient.
Copyright © 2020 The Korean Dermatological Association and The Korean Society for Investigative Dermatology.

Entities:  

Keywords:  Generalized; Lichen sclerosus et atrophicus

Year:  2020        PMID: 33911760      PMCID: PMC7992656          DOI: 10.5021/ad.2020.32.4.327

Source DB:  PubMed          Journal:  Ann Dermatol        ISSN: 1013-9087            Impact factor:   1.444


  8 in total

1.  Lichen sclerosus et atrophicus.

Authors:  H J Wallace
Journal:  Trans St Johns Hosp Dermatol Soc       Date:  1971

2.  Lichen sclerosus et atrophicus and autoimmunity--a study of 350 women.

Authors:  R H Meyrick Thomas; C M Ridley; D H McGibbon; M M Black
Journal:  Br J Dermatol       Date:  1988-01       Impact factor: 9.302

3.  Multicentre, phase II trial on the safety and efficacy of topical tacrolimus ointment for the treatment of lichen sclerosus.

Authors:  U R Hengge; W Krause; H Hofmann; R Stadler; G Gross; M Meurer; T Brinkmeier; P Frosch; I Moll; P Fritsch; K Müller; N Meykadeh; A Marini; T Ruzicka; H Gollnick
Journal:  Br J Dermatol       Date:  2006-11       Impact factor: 9.302

4.  Penile lichen sclerosus et atrophicus treated with clobetasol dipropionate 0.05% cream: a retrospective clinical and histopathological study.

Authors:  K Dahlman-Ghozlan; M A Hedblad; G von Krogh
Journal:  J Am Acad Dermatol       Date:  1999-03       Impact factor: 11.527

5.  Morphea and lichen sclerosus et atrophicus. Clinical and histopathologic studies in patients with combined features.

Authors:  J Uitto; D J Santa Cruz; E A Bauer; A Z Eisen
Journal:  J Am Acad Dermatol       Date:  1980-09       Impact factor: 11.527

6.  Lichen sclerosus et atrophicus. A study of 76 cases and their relation to diabetes.

Authors:  B García-Bravo; P Sánchez-Pedreño; A Rodríguez-Pichardo; F Camacho
Journal:  J Am Acad Dermatol       Date:  1988-09       Impact factor: 11.527

7.  Pulsed high-dose corticosteroids combined with low-dose methotrexate treatment in patients with refractory generalized extragenital lichen sclerosus.

Authors:  Alexander Kreuter; Christian Tigges; Renata Gaifullina; Julia Kirschke; Peter Altmeyer; Thilo Gambichler
Journal:  Arch Dermatol       Date:  2009-11

Review 8.  Diagnosis and treatment of lichen sclerosus: an update.

Authors:  Susanna K Fistarol; Peter H Itin
Journal:  Am J Clin Dermatol       Date:  2013-02       Impact factor: 7.403

  8 in total
  1 in total

Review 1.  Extragenital lichen sclerosus: a comprehensive review of clinical features and treatment.

Authors:  Aaron Burshtein; Joshua Burshtein; Sergey Rekhtman
Journal:  Arch Dermatol Res       Date:  2022-10-05       Impact factor: 3.033

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.